A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome

被引:27
作者
Dean, Diana J. [1 ,2 ]
Sabagha, Noor [1 ]
Rose, Kaitlin [1 ,3 ]
Weiss, Alexander [1 ]
France, John [4 ]
Asmar, Timothy [1 ]
Rammal, Jo-Ann [1 ]
Beyer, Margaret [1 ]
Bussa, Rebecca [1 ]
Ross, Jacob [1 ]
Chaudhry, Kaleem [1 ]
Smoot, Thomas [5 ]
Wilson, Kathleen [1 ]
Miller, Joseph [1 ,4 ]
机构
[1] Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA
[2] Michigan Poison Ctr, Detroit, MI USA
[3] Cent Michigan Univ, Coll Med, Mt Pleasant, MI 48859 USA
[4] Wayne State Univ, Detroit, MI 48202 USA
[5] Frederick Mem Hosp, Frederick, MD USA
关键词
EMERGENCY-DEPARTMENT; OSTEOARTHRITIS; SEVERITY; EFFICACY; NAUSEA;
D O I
10.1111/acem.14062
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives Patients with cannabinoid hyperemesis syndrome (CHS) present frequently to the emergency department. Previous case studies suggest dramatic symptomatic improvement with topical capsaicin treatment. This exploratory study examined the potential effectiveness of topical capsaicin in patients with nausea and vomiting due to a suspected CHS exacerbation. Methods This was a double-blind, randomized placebo-controlled pilot trial. Adults who presented with vomiting suspected to be from CHS were eligible for enrollment. We excluded pregnant women and those with resolution of symptoms. Following randomization, topical 0.1% capsaicin or placebo cream was applied to the anterior abdomen in a uniform manner. The primary outcome was the severity of nausea on a visual analog scale (VAS) of 0 to 10 cm assessed at 30 minutes. Secondary outcomes were adverse events, occurrence of posttreatment vomiting, nausea by VAS at 60 minutes, and hospital admission. Results This pilot trial enrolled 30 patients, 17 in the capsaicin arm and 13 in the placebo arm. One patient in the capsaicin arm did not tolerate treatment due to skin irritation. Mean +/- SD nausea severity at 30 minutes was 4.1 +/- 2.3 cm in the capsaicin arm and 6.1 +/- 3.3 cm in the placebo arm (difference = -2.0 cm, 95% confidence interval [CI] = 0.2 to -4.2 cm). At 60 minutes, mean +/- SD nausea severity was 3.2 +/- 3.2 cm versus 6.4 +/- 2.8 cm (difference = -3.2 cm, 95% CI = -0.9 to -5.4 cm). The percent reduction in nausea at 60 minutes from baseline was 46.0% in the capsaicin arm and 24.9% in the placebo arm (difference = 21.1%, 95% CI = -5.6% to 47.9%). A higher proportion of capsaicin group patients (29.4% vs. 0%) had complete resolution of nausea (relative risk = 3.4, 95% CI = 1.6 to 7.1). Conclusion In this pilot trial, the application of topical capsaicin cream was associated with a significant reduction in nausea at 60 minutes but not at 30 minutes and provided more complete relief of nausea.
引用
收藏
页码:1166 / 1172
页数:7
相关论文
共 27 条
  • [1] Topical Therapy for Osteoarthritis: Clinical and Pharmacologic Perspectives
    Altman, Roy
    Barkin, Robert L.
    [J]. POSTGRADUATE MEDICINE, 2009, 121 (02) : 139 - 147
  • [2] [Anonymous], 2016, Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health
  • [3] Recent trends in cyclic vomiting syndrome-associated hospitalisations with liberalisation of cannabis use in the state of Colorado
    Bhandari, Sanjay
    Jha, Pinky
    Lisdahl, Krista M.
    Hillard, Cecilia J.
    Venkatesan, Thangam
    [J]. INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 649 - 655
  • [4] Olvanil: A non-pungent TRPV1 activator has anti-emetic properties in the ferret
    Chu, Kit-Man
    Ngan, Man-Piu
    Wai, Man-Keung
    Yeung, Chi-Kong
    Andrews, Paul L. R.
    du Sert, Nathalie Percie
    Rudd, John A.
    [J]. NEUROPHARMACOLOGY, 2010, 58 (02) : 383 - 391
  • [5] Ultra-low doses of the transient receptor potential vanilloid 1 agonist, resiniferatoxin, prevents vomiting evoked by diverse emetogens in the least shrew (Cryptotis parva)
    Darmani, Nissar A.
    Henry, Denise A.
    Zhong, Weixia
    Chebolu, Seetha
    [J]. BEHAVIOURAL PHARMACOLOGY, 2020, 31 (01): : 3 - 14
  • [6] Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series
    Dezieck, Laurel
    Hafez, Zachary
    Conicella, Albert
    Blohm, Eike
    O'Connor, Mark J.
    Schwarz, Evan S.
    Mullins, Michael E.
    [J]. CLINICAL TOXICOLOGY, 2017, 55 (08) : 908 - 913
  • [7] Galli Jonathan A, 2011, Curr Drug Abuse Rev, V4, P241
  • [8] Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents: A Case Series
    Graham, Jessica
    Barberio, Michael
    Wang, George Sam
    [J]. PEDIATRICS, 2017, 140 (06)
  • [9] Challenges in Quantifying Marijuana Use
    Gray, Kevin M.
    Watson, Noreen L.
    Christie, Douglas K.
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2009, 18 (02) : 178 - 179
  • [10] Guedes V, 2018, REUMATOL CLIN, V14, P40, DOI 10.1016/j.reuma.2016.07.008